GSK vs. AZN, HLN, SN, CTEC, HIK, HCM, INDV, GNS, SPI, and ONT
Should you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Haleon (HLN), Smith & Nephew (SN), ConvaTec Group (CTEC), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Genus (GNS), Spire Healthcare Group (SPI), and Oxford Nanopore Technologies (ONT). These companies are all part of the "medical" sector.
GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.
GSK currently has a consensus target price of GBX 1,675.63, suggesting a potential downside of 3.70%. AstraZeneca has a consensus target price of £118, suggesting a potential downside of 1.90%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts clearly believe AstraZeneca is more favorable than GSK.
GSK has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500.
AstraZeneca received 772 more outperform votes than GSK when rated by MarketBeat users. Likewise, 63.64% of users gave AstraZeneca an outperform vote while only 50.19% of users gave GSK an outperform vote.
AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
GSK has a net margin of 14.59% compared to AstraZeneca's net margin of 13.30%. GSK's return on equity of 38.78% beat AstraZeneca's return on equity.
44.8% of GSK shares are owned by institutional investors. Comparatively, 50.7% of AstraZeneca shares are owned by institutional investors. 1.6% of GSK shares are owned by insiders. Comparatively, 0.1% of AstraZeneca shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, AstraZeneca had 1 more articles in the media than GSK. MarketBeat recorded 8 mentions for AstraZeneca and 7 mentions for GSK. AstraZeneca's average media sentiment score of 0.19 beat GSK's score of 0.04 indicating that AstraZeneca is being referred to more favorably in the news media.
GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 3.4%. AstraZeneca pays an annual dividend of GBX 228 per share and has a dividend yield of 1.9%. GSK pays out 5,504.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca pays out 7,125.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.
Summary
AstraZeneca beats GSK on 13 of the 20 factors compared between the two stocks.
Get GSK News Delivered to You Automatically
Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
